Suggested slug: nad-plus-research

Status: Locked citation-verified draft for a standalone facts page. Not published. Not for WordPress. Another agent may convert this to HTML. Do not add PMIDs, NCT numbers, CAS, UNII, or PubChem CIDs that are not on the Allowed lists below.

Workspace check (16 August 2026). No /workspace/nad-research-draft* or /workspace/nad-source-log* existed before this pass. /workspace/nad.html is a 214-byte SiteGround captcha redirect and was ignored. Product-label PNGs (nad-500mg-*.png, nad-mg-*.png) were not used as identity sources. This markdown is a new citation-verified facts draft modeled on the MOTS-c / Melanotan II locked notes.

Research date: 16 August 2026, America/Indianapolis (ET / UTC-4).

Research-use-only framing. This page describes an investigational laboratory research coenzyme. It is not medical advice. Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application. No human dosing, reconstitution, or administration protocol appears on this page. The opened 500 mg product page prints a subcutaneous “dosage chart,” reconstitution volumes, and injection-technique language. That vendor copy is excluded from this draft and is not a protocol.

One-sentence identity. NAD+ (nicotinamide adenine dinucleotide; oxidized form; USAN/INN nadide) is an essential dinucleotide coenzyme, not a peptide, with opened PubChem CID 5892, CAS 53-84-9, UNII 0U46U6E8UK, formula C21H27N7O14P2, MW 663.4 g/mol, InChIKey BAWFJGJZGIEFAR-NNYOXOHSSA-N. IUPHAR ligand 2451 (type Metabolite; approved: false). It is not NADH, not nicotinamide riboside (NR), not nicotinamide mononucleotide (NMN), not niacin / nicotinic acid, and not nicotinamide / niacinamide. Human efficacy of a research-market 500 mg or 1000 mg vial is not established. openFDA Drugs@FDA search=nadide returned HTTP 404.

–-

SRP product and index pages do not print CAS, UNII, PubChem CID, molecular formula, salt form, hydrate vs anhydrous, or a public COA. Identity below is taken only from opened public registries and from primary papers that name NAD+ / NAD / nadide / nicotinamide adenine dinucleotide / β-NAD+ / coenzyme I.

Opened SRP 500 mg product page (16 August 2026): title “NAD+ 500 mg Cellular Metabolism Research Vial”. Also-known-as line: Nicotinamide Adenine Dinucleotide, β-NAD+. Price printed $45.00. Subhead: “NAD+ (500 mg / 3 mL Vial).” Bullets: 500 mg lyophilized research compound in a 3 mL research vial; COA available for batch verification; Made in the USA; high-purity research material; intended for qualified laboratory and analytical research; securely packaged; For Research Use Only. Not for human or veterinary use. Description: listed for qualified laboratory research use only. Research category: Cellular Health Research. COA verified; third-party tested when available; 3 ml Vial. Footer-style note: not intended for human consumption, medical use, diagnostic use, or treatment of any disease. Availability: “10 in stock (can be backordered).” Shipping-box fields: Weight 1 lbs; Dimensions 1 × .5 × 2 in. Reviews (0).

Excluded from this draft (present on the opened 500 mg page, not used): a “NAD+ Dosage Chart” with subcutaneous daily milligram amounts, bacteriostatic-water reconstitution volumes, insulin-syringe unit conversions, a multi-week titration table, supplies-needed vial counts, injection-technique steps, lifestyle-advice copy, and “potential benefits / side effects” language. Those blocks are vendor human-use copy. They are not reproduced here and are not a laboratory protocol.

Opened SRP 1000 mg product page (16 August 2026): title “NAD+ 1000 mg Cellular Metabolism Research Vial”. Price printed $65.00. Bullets: 1000 mg lyophilized NAD+ research material; batch documentation available; U.S.-made; intended for qualified laboratory and analytical research; For Research Use Only. Not for human or veterinary use. Description: naturally occurring coenzyme involved in cellular redox reactions and energy metabolism; supplied for mitochondrial, metabolic, and cellular-aging research. Research category: Cellular Health Research. Handling note on that page is laboratory storage / PPE language, not a human protocol. Availability: “25 in stock (can be backordered).” Shipping-box: Weight 1 lbs; Dimensions 1 × .5 × 2 in. Reviews (0).

Not printed on either opened product page and therefore not claimed as SRP-verified: CAS; UNII; CID; formula; InChIKey; free acid vs lithium salt vs hydrate; a public COA file; a published laboratory amount.

Opened SRP index card (compound-research-guides / local 1674.html snapshot, 16 August 2026): “NAD+ (1000 mg Vial)” and “NAD+ (500 mg Vial)” under Metabolic; both tagged Evidence profile (not “Dedicated evidence guide”); both link to #nad-plus and to the product URLs above. Evidence-profile block title NAD+; house tier Established biology; intervention-specific gaps; class Cellular-metabolism research. Overview: “Nicotinamide adenine dinucleotide (NAD+) is an essential coenzyme in redox metabolism and a substrate for enzymes such as sirtuins and PARPs. It is not a peptide.” Mechanism: “NAD+/NADH couples support energy metabolism, while NAD+-consuming enzymes connect the molecule to DNA repair, stress responses, and signaling.” Evidence: “The biology is extensive, but evidence for a particular exogenous NAD+ formulation, route, or claimed outcome must be evaluated separately. Precursor studies are not automatically evidence for NAD+ itself.” Quality note: “State the exact molecular form, assay purity, and stability. Do not merge evidence for NR, NMN, niacin, and NAD+.” Last editorial review printed on that index: August 2026.

Opened dedicated-guide URLs http://simpleresearchpeptides.com/research-compound-directory/nad-plus-research/ and http://simpleresearchpeptides.com/research-compound-directory/nad-research-guide/ returned HTTP 404 on 16 August 2026. This draft is written for that missing page.

Critical identity point. CID 5892 / UNII 0U46U6E8UK is the oxidized dinucleotide (NAD+ / nadide). NADH is a different molecule (CID 439153; CAS 58-68-4; UNII 4J24DQ0916; formula C21H29N7O14P2; MW 665.4; InChIKey BOPGDPNILDQYTO-NNYOXOHSSA-N). An SRP “NAD+ 500 mg” or “1000 mg” lot is not automatically NADH, not a lithium salt, not a hydrate, and not a precursor vitamin. Confirm oxidized vs reduced form, salt, hydrate, and purity on a COA / LC-MS / NMR.

Registry chaos that must not be collapsed.

• PubChem CID 5892 depositor synonyms include “beta-Nicotinamide adenine dinucleotide, reduced.” That string sits on the oxidized CID. It is nomenclature noise, not identity. NADH is CID 439153.
• PubChem synonyms also include “NAD Lithium salt” and several hydrate catalog strings. Those sit on the free / inner-salt CID. They do not prove the SRP counter-ion or hydration state.
• Additional CAS RNs 64417-72-7, 4090-29-3, and 477981-33-2 appear on CID 5892. Only 53-84-9 is treated as the primary opened CAS (first synonym CAS + NCATS primary). The extras were not opened as separate substances.
• NCATS UNII 0U46U6E8UK is titled NADIDE and prints the NAD+ formula / InChIKey, but the prose block on that page conflates NADIDE with Enada (NADH) (“NADIDE (NADH)”, “Enada by Birkmayer”, “First approved in 2010”, oral 2.5–5 mg Enada language, chronic-fatigue / Parkinson claims). Enada is a NADH synonym on CID 439153, not proof that NAD+ is an approved drug. That NCATS marketing/prose block is unused as NAD+ approval, unused as NADH identity for this SKU, and unused as a dose. NCATS structure data (formula, InChIKey, CAS 53-84-9, UNII) remain usable.
• ClinicalTrials.gov NAD+ / nadide / nicotinamide adenine dinucleotide is a lexical collision (totalCount 261). Hits include Niagen / NR trials (example: NCT03482167 intervention is Niagen®, not NAD+), NMN trials, and unrelated “NAD” substrings. Unused as a trial census.
• IUPHAR ligand 2451 is NAD (metabolite, not approved). Do not invent a peptide ligand.

–-

Catalog “Cellular Health / Metabolic / longevity” language does not convert a research dinucleotide into a precursor vitamin, a reduced cofactor, or a peptide.

The 500 mg vial is not the 1000 mg vial. Two SRP SKUs. Same research name. No opened paper tested an SRP lot.

NAD+ is not a peptide. It is a dinucleotide coenzyme. The SRP index states this explicitly. Do not file it with peptide bioregulators.

NAD+ is not NADH. One hydride / two electrons and two protons of mass separate them (663.4 vs 665.4; InChIKeys share the stereo suffix NNYOXOHSSA-N but have different first blocks: BAWFJGJZGIEFAR vs BOPGDPNILDQYTO). NCATS/Enada prose that writes “NADIDE (NADH)” is a registry error, not chemistry.

NAD+ is not NR, NMN, niacin, or nicotinamide. Those are biosynthetic precursors (or, for nicotinamide, also a product of NAD+-consuming enzymes). Yoshino 2018 (PMID 29249689) and Bogan & Brenner 2008 (PMID 18429699) exist to keep those streams apart. Grant 2019 (PMID 31572171) states that precursor data (example: NR raising plasma NAD+) are not a substitute for measuring infused NAD+ itself.

Do not equate this vial with NADH, Enada, NR / Niagen, NMN, niacin / Niaspan, nicotinamide, tryptophan, MOTS-c, or an FDA-approved metabolic drug. Research use only.

–-

Opened reviews support a redox-coenzyme plus NAD+-consuming-enzyme working model. It is not a treatment claim. It was not generated with an SRP 500 mg or 1000 mg vial. Observed means a measurement in an opened paper. Proposed means a hypothesis. Not shown means the opened papers did not establish it for a research-market lot.

Observed — redox cofactor and NAD+-consuming enzymes (reviews) Covarrubias, Perrone, Grozio and Verdin 2021 (PMID 33353981; PMC 7963035; *Nat Rev Mol Cell Biol*) open: NAD+ is a coenzyme for redox reactions and an essential cofactor for non-redox NAD+-dependent enzymes, including sirtuins, CD38, and poly(ADP-ribose) polymerases. It can influence metabolic pathways, DNA repair, chromatin remodelling, cellular senescence, and immune-cell function. Ageing is recognised as accompanied by a gradual decline in tissue and cellular NAD+ in rodents and humans; the authors link that decline to ageing-associated conditions and state that “much remains to be learnt” about how to restore NAD+ safely in ageing humans. Review language that “many of these ageing-associated diseases can be slowed down and even reversed by restoring NAD+ levels” is review opinion / preclinical synthesis, not an approval and not a finding for this vial.

Canto, Menzies and Auwerx 2015 (PMID 26118927; PMC 4487780) review NAD+ as a cofactor that can rewire metabolism, activate sirtuins, and maintain mitochondrial fitness. Imai and Guarente 2014 (PMID 24786309; PMC 4112140) review NAD+ as both a redox coenzyme and a substrate for sirtuins, PARPs, and CD38/157, with NAMPT-mediated biosynthesis coupled to SIRT1. Chini, Zeidler, Kashyap, Warner and Chini 2021 (PMID 33930322; PMC 8172449) add that NAD pathway metabolites also participate in signaling, post-translational modification, epigenetics, and NAD-capping of RNA, and that NAD half-life can be on the order of minutes in some tissues. Migaud, Ziegler and Baur 2024 (PMID 39026037; PMC 12456757) review regulation and challenges in targeting NAD+ metabolism, including “limitations of, assumptions about and unappreciated factors that might influence the success or contribute to risks of NAD+ supplementation.”

Observed — CD38 as an age-linked NAD+ consumer (mice) Camacho-Pereira et al. 2016 (PMID 27304511; PMC 4911708; *Cell Metab*) report that CD38 expression and NADase activity increase with aging in mice, that CD38 is required for age-related NAD decline and mitochondrial dysfunction via a pathway mediated at least in part by SIRT3, and that CD38 is the main enzyme degrading the precursor NMN in vivo. Mouse enzymology. Not a human CD38-drug trial. Not this vial.

Observed — direct intravenous NAD+ changes the human NAD+ metabolome (pilot, not a protocol) Grant, Berg, Mestayer, Braidy, Bennett, Broom and Watson 2019 (PMID 31572171; PMC 6751327; *Front Aging Neurosci*) is the opened human paper that actually infuses NAD+ itself. Abstract: no published human data then existed on the fate of directly infused NAD+ (as opposed to NR). The study documented plasma and urine NAD+ and metabolites during and after a 6 h intravenous infusion at 3 μmol/min. No change in plasma NAD+ or listed metabolites (nicotinamide, methylnicotinamide, ADPR, NMN) until after 2 h; increased urinary methylnicotinamide and NAD+ at 6 h; no significant rise in urinary nicotinamide. Authors conclude that at that infusion rate NAD+ is rapidly and completely removed from plasma for at least the first 2 h; the metabolite profile is consistent with NAD+ glycohydrolase and NAD+ pyrophosphatase activity; urinary products include NAD+ itself and meNAM but not NAM. This is a 2019 pilot metabolome study. The printed infusion rate is a study condition, not a reconstitution or administration protocol for an SRP vial.

Observed — precursor vitamins raise NAD+ by a different route (distinction, not this SKU) Bogan and Brenner 2008 (PMID 18429699) evaluate nicotinic acid, nicotinamide, and nicotinamide riboside as distinct NAD+ precursor vitamins. Yoshino, Baur and Imai 2018 (PMID 29249689; PMC 5842119) review NMN and NR as key intermediates with tissue-specific fates. Trammell et al. 2016 (PMID 27721479; PMC 5062546) report oral NR is bioavailable in mice and humans and raises the blood NAD+ metabolome. Airhart et al. 2017 (PMID 29211728; PMC 5718430) is an open-label NR PK study. Yoshino et al. 2021 (PMID 33888596; PMC 8550608) is a 10-week randomized NMN trial in postmenopausal women with prediabetes. These papers are precursor evidence. They are not evidence that an SRP NAD+ vial is orally bioavailable, and they are not NAD+ infusion data.

Not shown / do not infer

• That an SRP 500 mg or 1000 mg lyophilized lot is chemically identical to the Grant 2019 infusate.
• That precursor (NR / NMN / niacin / nicotinamide) human outcomes transfer to exogenous NAD+.
• That NCATS “approved 2010 / Enada” language is an FDA approval of NAD+.
• A completed human efficacy, safety, or aging-indication package for NAD+ as a drug.
• Oral bioavailability of intact NAD+ in humans (Grant 2019 is intravenous and reports rapid plasma clearance).
• Any reconstitution, injection, or infusion method for this SKU.

Mechanism in one line. Oxidized dinucleotide coenzyme for redox metabolism and substrate for sirtuins, PARPs, and CD38; tissue NAD+ declines with age in opened reviews; direct human infusion data are a single opened pilot metabolome study. Not a treatment claim. Not for human use.

–-

Label every row. NAD+ ≠ NADH ≠ NR ≠ NMN ≠ niacin ≠ nicotinamide. Review “therapeutic potential” language is not a completed therapeutic program.

A. Opened NAD+ biology / mechanism reviews and primary enzymology Covarrubias 2021 (PMID 33353981); Migaud 2024 (PMID 39026037); Chini 2021 (PMID 33930322); Rajman 2018 (PMID 29514064); Verdin 2015 (PMID 26785480); Canto 2015 (PMID 26118927); Imai & Guarente 2014 (PMID 24786309); Lautrup 2019 (PMID 31577933); Waddell 2023 (PMID 37174729); Belenky 2007 (PMID 17161604). Primary mouse CD38: Camacho-Pereira 2016 (PMID 27304511).

B. Opened direct human NAD+ administration paper Grant 2019 (PMID 31572171) — 6 h IV NAD+ metabolome pilot. No NCT printed on the opened Europe PMC record. Do not invent one.

C. Opened interventional registrations that name NAD+ or Coenzyme I — no results

• NCT07328100 (NAD-VA; Shanghai 10th People’s Hospital; Coenzyme I for Injection vs NaCl; vascular aging; randomized, triple-blind; estimated n=60; NOT_YET_RECRUITING; isFdaRegulatedDrug false; hasResults false). Brief summary itself distinguishes precursor (NR/NMN) arterial-stiffness literature from the unanswered question about NAD+ / Coenzyme I.
• NCT06558253 (Anhui Provincial Hospital; Coenzyme I for Injection after single-unit unrelated cord-blood transplant; Phase 1 open-label sequential; estimated n=12; RECRUITING; isFdaRegulatedDrug false; hasResults false). Printed arm amounts on that record are study conditions and are not reproduced here.
• NCT06919328 (Nutraceuticals Research Institute / ChromaDex collaborator; injectable Niagen® vs NAD+ vs placebo by IM / SQ / IV-push; estimated n=70; RECRUITING; isFdaRegulatedDrug false; hasResults false). Primary outcomes on the opened record are pain / subjective discomfort, not NAD+ restoration efficacy.

Registration is not efficacy, safety, or FDA endorsement.

D. Precursor human / review stream — distinction only Yoshino 2018 (PMID 29249689); Bogan 2008 (PMID 18429699); Trammell 2016 (PMID 27721479); Airhart 2017 (PMID 29211728); Yoshino 2021 (PMID 33888596); Zhang 2016 mouse NAD+ repletion (PMID 27127236). Unused as NAD+ vial evidence.

E. Lexical / unused CT.gov Broad NAD+ / nadide / nicotinamide-adenine-dinucleotide intervention queries: totalCount 261. Example unused hit: NCT03482167 (“NAD Therapy…”) intervention is Niagen® (NR), not NAD+. Do not cite NR/NMN NCTs as NAD+ trials.

Regulatory — not FDA-approved; NCATS Enada prose is NADH conflation openFDA nadide: 404. IUPHAR approved: false. NCATS “First approved in 2010 / Enada” block is NADH dietary-supplement marketing on the NADIDE record. Unused as an NAD+ NDA.

Vendor identity — not independently verified SRP prints the name “NAD+,” 500 mg or 1000 mg, “COA available” / “batch documentation,” and research-use-only footers, but does not display CAS, UNII, CID, salt, hydrate, or a public COA file.

–-

Read the “what it did not show” column. Published study designs are historical facts from those papers. They are not a protocol. Infusion rates, oral precursor amounts, and mouse schedules are study conditions, not instructions for an SRP 500 mg or 1000 mg research vial.

Human / NCT snapshot. One opened published direct-NAD+ human metabolome pilot (PMID 31572171, no NCT on that record). Three opened registrations that name NAD+ or Coenzyme I (NCT07328100, NCT06558253, NCT06919328), none with results. Do not invent additional administration NCTs. Do not treat NR/NMN NCTs as NAD+ trials.

–-

These are gaps. Treating any of them as settled is incorrect.

• No completed human efficacy package for exogenous NAD+ as a drug. Grant 2019 is a metabolome pilot. The three opened NCTs have no results.
• No proof the SRP vial is CID 5892 inner-salt NAD+. CAS, UNII, salt, hydrate, and a public COA were not printed. PubChem lists lithium-salt and hydrate catalog strings on the same CID.
• No FDA-approved therapeutic use of NAD+ / nadide. openFDA nadide 404. IUPHAR approved: false. NCATS “2010 / Enada” prose is NADH conflation.
• Precursor outcomes are not NAD+ outcomes. NR, NMN, niacin, and nicotinamide papers do not validate this vial.
• NADH / Enada findings are not NAD+. Different CID, CAS, UNII, formula, and InChIKey.
• Oral intact-NAD+ bioavailability in humans is not shown on the opened Grant record (IV; rapid plasma removal).
• Aging, addiction, cognitive, or metabolic treatment claims for a research-market vial are not established.
• No opened PK, chronic toxicology, carcinogenicity, or reproductive-tox package for an SRP 500 mg or 1000 mg vial. Historical infusion rates and precursor oral amounts are not instructions.

–-

Each card is a single opened record. Reviews are secondary unless noted. Historical infusion rates and precursor amounts are study conditions, not instructions. NCTs are listed as registrations, not results.

Grant et al., 2019 — Front Aging Neurosci. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD. Direct NAD+ (not NR) infusion; delayed plasma rise; urinary NAD+ and meNAM; rapid plasma clearance. Not a protocol. PMID 31572171. DOI 10.3389/fnagi.2019.00257. PMC 6751327.

Covarrubias, Perrone, Grozio, Verdin, 2021 — Nat Rev Mol Cell Biol. NAD+ metabolism and its roles in cellular processes during ageing. Redox + sirtuin / CD38 / PARP; age-linked decline; open questions on human restoration. Secondary review. PMID 33353981. PMC 7963035.

Migaud, Ziegler, Baur, 2024 — Nat Rev Mol Cell Biol. Regulation of and challenges in targeting NAD+ metabolism. Secondary review; emphasizes limitations and possible risks of supplementation strategies. PMID 39026037. PMC 12456757.

Chini et al., 2021 — Cell Metab. Evolving concepts in NAD+ metabolism. Secondary perspective. PMID 33930322. PMC 8172449.

Rajman, Chwalek, Sinclair, 2018 — Cell Metab. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Secondary review of boosting strategies (mostly precursors / animal data). PMID 29514064. PMC 6342515.

Canto, Menzies, Auwerx, 2015 — Cell Metab. NAD(+) metabolism and the control of energy homeostasis. Secondary review. PMID 26118927. PMC 4487780.

Imai & Guarente, 2014 — Trends Cell Biol. NAD+ and sirtuins in aging and disease. Secondary review. PMID 24786309. PMC 4112140.

Camacho-Pereira et al., 2016 — Cell Metab. CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism. Mouse primary. PMID 27304511. PMC 4911708.

Verdin, 2015 — Science. NAD⁺ in aging, metabolism, and neurodegeneration. Secondary review. Title/DOI confirmed. PMID 26785480.

Lautrup, Sinclair, Mattson, Fang, 2019 — Cell Metab. NAD+ in brain aging and neurodegenerative disorders. Secondary review. PMID 31577933. PMC 6787556.

Waddell, Khatoon, Kristian, 2023 — Cells. Cellular and mitochondrial NAD homeostasis in health and disease. Secondary review. PMID 37174729. PMC 10177113.

Belenky, Bogan, Brenner, 2007 — Trends Biochem Sci. NAD+ metabolism in health and disease. Secondary review. PMID 17161604.

Yoshino, Baur, Imai, 2018 — Cell Metab. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Distinction review. Not this SKU. PMID 29249689. PMC 5842119.

Bogan & Brenner, 2008 — Annu Rev Nutr. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Distinction review. PMID 18429699.

Trammell et al., 2016 — Nat Commun. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. NR, not NAD+. PMID 27721479. PMC 5062546.

Airhart et al., 2017 — PLoS One. Open-label NR pharmacokinetics and blood NAD+ in healthy volunteers. NR, not NAD+. PMID 29211728. PMC 5718430.

Yoshino M. et al., 2021 — Science. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. NMN RCT, not NAD+. PMID 33888596. PMC 8550608.

Zhang et al., 2016 — Science. NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice. Mouse precursor-repletion context. PMID 27127236.

NCT07328100 — ClinicalTrials.gov. Coenzyme I for Injection vs NaCl in vascular aging. Not yet recruiting. No results. Registration ≠ efficacy.

NCT06558253 — ClinicalTrials.gov. Coenzyme I for Injection after sUCBT. Phase 1, recruiting. No results.

NCT06919328 — ClinicalTrials.gov. Injectable NR vs NAD+ vs placebo (tolerability). Recruiting. No results.

–-

NAD+ is an investigational laboratory research coenzyme. It is not an FDA-approved drug for human use. This page is educational. It does not provide dosing, reconstitution, administration, or any human-use instructions. The 500 mg and 1000 mg masses are vendor listings, not published laboratory protocols.

Simple Research Peptides (SRP) materials are for laboratory research only and are not for human or veterinary use, consumption, administration, diagnosis, treatment, or therapeutic application.

Laboratory identity is the first practical issue. Opened registries describe NAD+ / nadide as CID 5892 / CAS 53-84-9 / UNII 0U46U6E8UK / C21H27N7O14P2 / InChIKey BAWFJGJZGIEFAR-NNYOXOHSSA-N; IUPHAR ligand 2451, not approved. SRP product pages do not print CAS, UNII, salt, hydrate, or a public COA. A method written for NADH, NR, NMN, niacin, nicotinamide, or a peptide is not automatically valid for this vial.

Confirm oxidized vs reduced form (NAD+ vs NADH), salt, hydration state, and purity by LC-MS / NMR / enzymatic assay before treating a vial as the literature article. Independently sourced research material is not established as equivalent to the Grant 2019 infusate. Historical intravenous infusion rates and oral precursor amounts are study conditions from those papers. They are not a reconstitution scheme.

The opened 500 mg product page contains human-use reconstitution and injection copy. That copy is not adopted here.

No reconstitution scheme, no administration route, and no human or veterinary use protocol appears on this page. Research use only.

–-

Sources actually opened for this draft. Do not add PMIDs or NCTs that are not on the allowed list.

1. Grant R, Berg J, Mestayer R, et al. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD. *Front Aging Neurosci.* 2019;11:257. PMID 31572171. DOI 10.3389/fnagi.2019.00257. PMC 6751327. Direct human NAD+ infusion metabolome. Abstract.
2. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. *Nat Rev Mol Cell Biol.* 2021;22(2):119-141. PMID 33353981. DOI 10.1038/s41580-020-00313-x. PMC 7963035. Secondary review. Abstract.
3. Migaud ME, Ziegler M, Baur JA. Regulation of and challenges in targeting NAD+ metabolism. *Nat Rev Mol Cell Biol.* 2024;25(10):822-840. PMID 39026037. DOI 10.1038/s41580-024-00752-w. PMC 12456757. Secondary review. Abstract.
4. Chini CCS, Zeidler JD, Kashyap S, Warner G, Chini EN. Evolving concepts in NAD+ metabolism. *Cell Metab.* 2021;33(6):1076-1087. PMID 33930322. DOI 10.1016/j.cmet.2021.04.003. PMC 8172449. Secondary perspective. Abstract.
5. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. *Cell Metab.* 2018;27(3):529-547. PMID 29514064. DOI 10.1016/j.cmet.2018.02.011. PMC 6342515. Secondary review. Abstract.
6. Cantó C, Menzies KJ, Auwerx J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. *Cell Metab.* 2015;22(1):31-53. PMID 26118927. DOI 10.1016/j.cmet.2015.05.023. PMC 4487780. Secondary review. Abstract.
7. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. *Trends Cell Biol.* 2014;24(8):464-471. PMID 24786309. DOI 10.1016/j.tcb.2014.04.002. PMC 4112140. Secondary review. Abstract.
8. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through a SIRT3-dependent mechanism. *Cell Metab.* 2016;23(6):1127-1139. PMID 27304511. DOI 10.1016/j.cmet.2016.05.006. PMC 4911708. Mouse primary. Abstract.
9. Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. *Science.* 2015. PMID 26785480. DOI 10.1126/science.aac4854. Secondary review. Title/DOI confirmed (lite).
10. Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD+ in brain aging and neurodegenerative disorders. *Cell Metab.* 2019. PMID 31577933. DOI 10.1016/j.cmet.2019.09.001. PMC 6787556. Secondary review. Lite.
11. Waddell J, Khatoon R, Kristian T. Cellular and mitochondrial NAD homeostasis in health and disease. *Cells.* 2023;12(9):1329. PMID 37174729. DOI 10.3390/cells12091329. PMC 10177113. Secondary review. Lite.
12. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. *Trends Biochem Sci.* 2007. PMID 17161604. DOI 10.1016/j.tibs.2006.11.006. Secondary review. Lite.
13. Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. *Cell Metab.* 2018;27(3):513-528. PMID 29249689. DOI 10.1016/j.cmet.2017.11.002. PMC 5842119. Distinction (NR/NMN). Abstract.
14. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. *Annu Rev Nutr.* 2008;28:115-130. PMID 18429699. DOI 10.1146/annurev.nutr.28.061807.155443. Distinction (precursor vitamins). Abstract.
15. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. *Nat Commun.* 2016;7:12948. PMID 27721479. DOI 10.1038/ncomms12948. PMC 5062546. NR, not NAD+. Abstract.
16. Airhart SE, Shireman LM, Risler LJ, et al. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. *PLoS One.* 2017. PMID 29211728. DOI 10.1371/journal.pone.0186459. PMC 5718430. NR, not NAD+. Lite.
17. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. *Science.* 2021;372(6547):1224-1229. PMID 33888596. DOI 10.1126/science.abe9985. PMC 8550608. NMN, not NAD+. Abstract.
18. Zhang H, Ryu D, Wu Y, et al. NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice. *Science.* 2016. PMID 27127236. DOI 10.1126/science.aaf2693. Mouse repletion. Lite.
19. ClinicalTrials.gov NCT07328100, NCT06558253, NCT06919328 (opened JSON, versionHolder 2026-08-14; all hasResults false). Broad query.intr=NAD+ / nadide / nicotinamide adenine dinucleotide totalCount 261 (lexical; unused as a census). Unused example: NCT03482167 (Niagen®, not NAD+).
20. PubChem CID 5892 (Nadide; CAS 53-84-9; UNII 0U46U6E8UK). PUG properties, synonyms, xrefs opened 16 August 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5892
21. Distinction PubChem PUG/synonyms: NADH CID 439153; NR CID 439924; NMN CID 14180; nicotinic acid CID 938; nicotinamide CID 936.
22. NCATS UNII 0U46U6E8UK (NADIDE; CAS 53-84-9; PubChem 5892; InChIKey match). Enada/NADH prose unused as approval. https://drugs.ncats.io/drug/0U46U6E8UK
23. IUPHAR/BPS ligand 2451 (NAD; Metabolite; approved false). https://www.guidetopharmacology.org/services/ligands/2451
24. openFDA Drugs@FDA: nadide HTTP 404. Opened 16 August 2026.
25. SRP pages (opened 16 August 2026): 500 mg http://simpleresearchpeptides.com/product/nad-500-mg-vial/; 1000 mg http://simpleresearchpeptides.com/product/nad-1000-mg-vial-2/; index (Evidence profile; last editorial review August 2026). Dedicated-guide URLs /nad-plus-research/ and /nad-research-guide/ 404. For laboratory research only. Not for human or animal use.

Allowed PMID list used on this page: 31572171, 33353981, 39026037, 33930322, 29514064, 26118927, 24786309, 27304511, 26785480, 31577933, 37174729, 17161604. Distinction / precursor (not this SKU): 29249689, 18429699, 27721479, 29211728, 33888596, 27127236. Administration NCTs: NCT07328100, NCT06558253, NCT06919328 (no results). Opened PMC: PMC6751327, PMC7963035, PMC12456757, PMC8172449, PMC6342515, PMC4487780, PMC4112140, PMC4911708, PMC6787556, PMC10177113, PMC5842119, PMC5062546, PMC5718430, PMC8550608. Do not use PMID 31620080 (unrelated circulating-tumor-DNA paper that collided in an earlier title guess for Grant 2019).

–-

Product links are research materials, not treatment recommendations. Opened SRP pages: NAD+ 500 mg Cellular Metabolism Research Vial ($45.00); NAD+ 1000 mg Cellular Metabolism Research Vial ($65.00). Category Metabolic / Cellular Health Research. Footer: for laboratory research only; not for human or veterinary use. CAS, UNII, salt, hydrate, and a public COA were not printed. Do not confuse with NADH / Enada, NR / Niagen, NMN, niacin, nicotinamide, or mitochondrial peptides (MOTS-c, SS-31).

Educational information only. The SRP listings NAD+ 500 mg and NAD+ 1000 mg are research coenzyme materials corresponding, on opened registries, to NAD+ / nadide (CID 5892; CAS 53-84-9; UNII 0U46U6E8UK; C21H27N7O14P2; 663.4 g/mol; InChIKey BAWFJGJZGIEFAR-NNYOXOHSSA-N). It is not a peptide, not NADH, not NR, not NMN, not niacin, and not nicotinamide. IUPHAR ligand 2451, approved false. One opened published direct-NAD+ human metabolome pilot (PMID 31572171). Three opened administration NCTs, no results. Not FDA-approved. Salt and hydrate of an SRP lot are not printed. Historical infusion rates and precursor oral amounts are study conditions, not instructions. Laboratory research use only; not for human or animal use. Not medical advice. Not for human use. No human dosing protocol. Last source review: 16 August 2026 (America/Indianapolis). For laboratory research only. Not for human or veterinary use.